Amanote Research
Register
Sign In
First-Line Gefitinib Bei Nachweis Aktivierender EGFR-Mutationen
Best Practice Onkologie
- Germany
doi 10.1007/s11654-012-5010-x
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
February 1, 2012
Authors
Unknown
Publisher
Springer Science and Business Media LLC
Related search
Vor Therapie Nach EGFR-Mutationen Fahnden
Info Onkologie
PC04.01 Optimal Sequencing of EGFR TKI Therapy (Gefitinib/Erlotinib/Afatinib First Versus Osimertinib First)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Verbesserter Nachweis Einer Aspergillose Bei CF-Patienten
Allergo Journal
Allergy
Immunology
Array-Basierter Nachweis Chromosomaler Aberrationen Bei Malignen Neoplasien
Medizinische Genetik
Genetics
Combination of Chemotherapy and Gefitinib as First-Line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: A Randomized Controlled Trial
International Journal of Cancer
Cancer Research
Oncology
P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Central Nervous System Progression in Advanced Non–small Cell Lung Cancer Patients With EGFR Mutations in Response to First-Line Treatment With Two EGFR-TKIs, Gefitinib and Erlotinib: A Comparative Study
BMC Cancer
Cancer Research
Oncology
Genetics
Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC
Neoplasma
Cancer Research
